ChildrensJoin Children’s National Hospital for a pivotal symposium on the journey of AGAMREE® from academic research to market approval for DMD treatment in children. This event highlights the critical role of academic entrepreneurship and collaboration with industry in advancing treatments for rare diseases. Featuring insights from experts on the Vamorolone drug development program, regulatory pathways, and the venture philanthropy business model, this symposium is for those committed to making a difference in the biotech and healthcare sectors. Don't miss this opportunity to engage, learn, and network with leaders in the field.


3:00 – 3:25 PM - Registration and Networking

3:25 – 3:30 PM – Welcome remarks by Dr. Mark Batshaw

3:30-3:45 PM - Overview of the Vamorolone drug development program by Dr. Eric Hoffman

3:45-4:25 PM. The regulatory path of Vamorolone: Insights and innovations from parallel FDA and EMA approvals.

Panel Chair: Daniela Drago


Jesse Damsker, Eric Hoffman, John McCall, Kanneboyina Nagaraju, John van den Anker [ReveraGen],

Paula Clemens (University of Pittsburgh), Lauren Morgenroth (CEO TRiNDS LLC)


- Role of pre-clinical efficacy studies 

- Pediatric first-in-patient studies (4 to <7 years); choice of stage of disease

- Clinical trial design (dose ranging n=48; double-blind placebo

and prednisone-controlled n=121)

- Effective and rapid pivot during COVID to remote assessments

- Choice of novel primary outcome (time to stand from supine)

- Effective leveraging of International Academic Clinical Trial Consortium (CINRG)

- Discordant discussions with the FDA and EMA

- EMA PIP - enabling a broad age label at initial approval (FDA 2 years and older)

- Joint FDA-EMA inspection of Sponsor

- Contrasts of the FDA and EMA labels for Vamorolone

- Hand-off to marketing partner at NDA (Santhera)

4:25-4:35 PM Coffee break

4:35-5:20 PM. The venture philanthropy business model: Shared risk, shared benefit, and giving back to the non-profit sector.

Panel Chair: Sharon Hesterlee, Muscular Dystrophy Association

Panelists: Eric Hoffman, Jesse Damsker, John McCall [ReveraGen], Paula Clemens (University of Pittsburgh)


- Definition of venture philanthropy model; MDA's experience

- ReveraGen venture philanthropy model: where the $75M of non-dilutive funding came from

- The importance of 'de-risking' as a component of the model

- The importance of NIH NCATS TRND in early-stage de-risking

- The importance of federal sources of support (NIH, DoD, EU)

- Paying forward to the international non-profit research community (2/3rd of ReveraGen proceeds to non-profits)

- While this clearly worked, can it be done again?

5:20 – 5:50 PM Fireside Chat | Dr. Batshaw + Dr. Hoffman

5:50 -7:30 PM | Networking reception

Click here to register.